These findings suggest that TPs, through the involvement of TNF-α, IL-1 beta, and IL-6, could play a therapeutic role in treating obesity, liver inflammation, and fatty degeneration by inhibiting COX-2 and iNOS (50). The gene discussed is TNF; the disease is obesity due to melanocortin 4 receptor deficiency.